A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
ConditionSolid Malignancies
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmunome, Inc.
About this trial
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Eligibility criteria
Qualifiers
≥18 years of age
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2
Histological or cytological diagnosis of a solid tumor
Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit.
Disqualifiers
Participant has received certain prior radiation therapy as detailed in the protocol
Participant has undergone major surgery within 4 weeks or minor surgery within 2 weeks of starting 177Lu-IM-3050 or has known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis.
Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 3 years.
Recent or ongoing serious infection or other significant medical condition as detailed in the protocol.
Trial design
Treatments tested in this trial
- 177Lu-IM-3050
Treatment groups
105 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov